Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists

References

• Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505–524.25733955
   PubMed Web of Science ®Google Scholar
• Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169–179. doi:10.1093/bmb/ldv01725957394
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–378. doi:10.3109/15622975.2012.69614322834451
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. 2014 Available from: https://www.nice.org.uk/guidance/cg178. Accessed 1119, 2019.
   Google Scholar
• Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229. doi:10.1176/appi.ajp.2016.1605050327919182
   PubMed Web of Science ®Google Scholar
• Correll CU, Brevig T, Brain C. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. BMC Psychiatry. 2019;19:362. doi:10.1186/s12888-019-2318-x31727015
   PubMed Web of Science ®Google Scholar
• Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63–76. doi:10.1097/YIC.0b013e32836508e623995856
   PubMed Web of Science ®Google Scholar
• Kymes S, Sullivan C, Kinon B, Simonsen J, Hartry A. The cost of incident treatment-resistant schizophrenia in commercial insurance beneficiaries. Presented at the 31st Annual US Psychiatric and Mental Health Congress; October 25–28; 2018; Orlando, FL Available from: https://www.psychcongress.com/posters/cost-incident-treatment-resistant-schizophrenia-commercial-insurance-beneficiaries. Accessed 1119, 2019.
   Google Scholar
• Brain C, Kymes S, DiBenedetti DB, Brevig T, Velligan DI. Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study. BMC Psychiatry. 2018;18(1):253. doi:10.1186/s12888-018-1833-530103719
   PubMed Web of Science ®Google Scholar
• Velligan DI, Brain C, Duvold LB, Agid O. Caregiver burdens associated with treatment-resistant schizophrenia: a quantitative caregiver survey of experiences, attitudes and perceptions. Front Psychiatry. 2019;10:584. doi:10.3389/fpsyt.2019.0058431551821
   PubMed Web of Science ®Google Scholar
• Lally J, Ajnakina O, Di Forti M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46(15):3231–3240. doi:10.1017/S003329171600201427605254
   PubMed Web of Science ®Google Scholar
• Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981–1989. doi:10.1017/S003329171700043528395674
   PubMed Web of Science ®Google Scholar
• Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72(11):1439–1444. doi:10.4088/JCP.09m05785yel21457676
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156(4):544–549. doi:10.1176/ajp.156.4.54410200732
   PubMed Web of Science ®Google Scholar
• Samara MT, Nikolakopoulou A, Salanti G, Leucht S. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials. Schizophr Bull. 2019;45(3):639–646. doi:10.1093/schbul/sby09529982701
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opin. 1997;14(1):1–20. doi:10.1185/030079997091133389524789
   PubMed Web of Science ®Google Scholar
• Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses. 2010;4(1):49–55. doi:10.3371/CSRP.4.1.420643629
   PubMedGoogle Scholar
• Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L. Clozapine eligibility among state hospital patients. Schizophr Bull. 1996;22(1):15–25. doi:10.1093/schbul/22.1.158685657
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kanahara N, Yamanaka H, et al. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. 2015;227(2–3):278–282. doi:10.1016/j.psychres.2015.02.02125863824
   PubMed Web of Science ®Google Scholar
• Market Research Society (MRS). Code of conduct. 2014 Available from: https://www.mrs.org.uk/pdf/mrs%20code%20of%20conduct%202014.pdf. Accessed 1119, 2019.
   Google Scholar
• Council of American Survey Research Organizations (CASRO). Code of standards and ethics for market, opinion, and social research. Undated. Available from: https://www.insightsassociation.org/sites/default/files/misc_files/casrocode.pdf. Accessed 1119, 2019.
   Google Scholar
• EphMRA. Code of conduct. 2018 Available from: https://www.ephmra.org/media/2300/ephmra-code-of-conduct-august-2018-gdpr-update-v5-for-issue.pdf. Accessed 1119, 2019.
   Google Scholar
• Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017;62(11):772–777. doi:10.1177/070674371771816728655284
   PubMed Web of Science ®Google Scholar
• Wang G, Zheng W, Li XB, et al. ECT augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res. 2018;105:23–32. doi:10.1016/j.jpsychires.2018.08.00230144667
   PubMed Web of Science ®Google Scholar
• Long Y, Ouyang X, Liu Z, et al. Associations among suicidal ideation, white matter integrity and cognitive deficit in first-episode schizophrenia. Front Psychiatry. 2018;9:391. doi:10.3389/fpsyt.2018.0039130210372
   PubMed Web of Science ®Google Scholar
• Zhang XY, Du X, Yin G, et al. Prevalence and clinical correlates of and cognitive function at the time of suicide attempts in first-episode and drug-naive patients with schizophrenia. J Clin Psychiatry. 2018;79(4):17m11797. doi:10.4088/JCP.17m11797
   Web of Science ®Google Scholar
• Villa J, Choi J, Kangas JL, Kaufmann CN, Harvey PD, Depp CA. Associations of suicidality with cognitive ability and cognitive insight in outpatients with schizophrenia. Schizophr Res. 2018;192:340–344. doi:10.1016/j.schres.2017.06.01328655480
   PubMed Web of Science ®Google Scholar
• Delaney C, McGrane J, Cummings E, et al. Preserved cognitive function is associated with suicidal ideation and single suicide attempts in schizophrenia. Schizophr Res. 2012;140(1–3):232–236. doi:10.1016/j.schres.2012.06.01722796150
   PubMed Web of Science ®Google Scholar
• Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment. 2012;916198.22966451
   PubMedGoogle Scholar
• Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170(6):609–615. doi:10.1176/appi.ajp.2013.1205067423558429
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036–1042. doi:10.1038/s41386-018-0278-330514883
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L. Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol. 2013;33(1):80–83. 23277247
   PubMed Web of Science ®Google Scholar
• Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75–85. doi:10.1093/oxfordjournals.schbul.a0333159502547
   PubMed Web of Science ®Google Scholar
• Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975–983. doi:10.1001/archpsyc.62.9.97516143729
   PubMed Web of Science ®Google Scholar
• Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785–1804. doi:10.1176/appi.ajp.162.10.178516199825
   PubMed Web of Science ®Google Scholar
• Kane JM, Robinson DG, Schooler NR, et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am J Psychiatry. 2016;173(4):362–372. doi:10.1176/appi.ajp.2015.1505063226481174
   PubMed Web of Science ®Google Scholar
• Godin O, Leboyer M, Schürhoff F, et al.; FACE-SZ (FondaMental Academic Centers of Expertise for schizophrenia) group. Metabolic syndrome and illness severity predict relapse at 1-year follow-up in schizophrenia: the FACE-SZ cohort. J Clin Psychiatry. 2018;79(6):17m12007. doi:10.4088/JCP.17m12007
   Web of Science ®Google Scholar
• Chouinard G, Samaha AN, Chouinard VA, et al. Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom. 2017;86(4):189–219. doi:10.1159/00047731328647739
   PubMed Web of Science ®Google Scholar
• Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27(11):2979–2986. doi:10.1523/JNEUROSCI.5416-06.200717360921
   PubMed Web of Science ®Google Scholar